Blood-tracking device uses new technology

(HealthDay)—The first device to use Radio Frequency Identification (RFID) technology to help workers track blood products and prevent the release of unsuitable samples has been approved by the U.S. Food and Drug Administration.

The iTrace for Blood Centers device uses a memory-storage chip on the item being tracked. In addition to barcode identification systems already in place, the new device provides another layer of protection in product tracking, the agency said in a news release.

The device can track information including a product code, blood type and expiration date, the FDA said.

iTrace is manufactured by SysLogic Inc., based in Brookfield, Wis.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Kcentra approved to stop severe bleeding in heart patients

Apr 30, 2013

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...

Judges side with FDA in rejecting stem cell device

Mar 22, 2013

(AP)—A federal appeals court is siding with the Food and Drug Administration in a case brought by medical device maker Cytori, ruling that the agency was correct to reject fast-track approval for two company devices used ...

Drug approved for inherited blood disorder

Jan 24, 2013

(HealthDay)—Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

13 hours ago

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

16 hours ago

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.